Succesful Treatment of Statin-induced myositis

[sylviak]

According to Ballantyne , et al (2003) , statin induced myositis can be treated succesfully by discontinuation of the statin, by steriods or by non-inflammatory drugs.
Dr. Sobajo, et al, in the UK treated the patients through discontinuation of the statinand by NSAIDS.

Full text of the article
*http://www.medwelljournals.com/fulltext/tc/2007/24-26.pdf

[cjbrooksjc]

Sylvia: You might be interested in these as well:

**http://www.ncbi.nlm.nih.gov/pubmed/17241784

and

**http://www.ncbi.nlm.nih.gov/pubmed/19534648

Best,

Brooks

[sylviak]

Thank you.I've bookmarked the page and noted the names of the authors.
I'll get the full text and contact the authors.

[sylviak]

The paper written by Betowski et al (2009) is excellent. Thanks Brooks for the link. It is about to be published next month.I have received an advanced copy of the article wherein the author(s) document the probable causes of each effects. The author(s) also state the treatments.
I quote," Treatment of this condition (rhabdomyolisis) usually need hospitalisation .Treatment of this condition includes parenteral hydration,administration of mannitol carbonates to stimulate osmotic diuresis and alkalinize urine(to inhibit precipitation of myoglobin inside renal tubules), as well as careful monitoring of plasma K+ since
hyperkalemia may induce life-threatening arrhythmias."
The entire text is worth reading for those looking for an understanding of the side effects, cure and treatment.

[sylviak]

A certain Anthony William Linnane from the Center of Molecular Biology filed a patent application to treat statin side effects.
*https://register.epoline.org/espacenet/application;jsessionid=4F3CB2503EE480AFEC85134BBFA84996.RegisterPlus_prod_1?number=EP01998341&index[0]=publication&value[0]=EP1343488

Abstract :
The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof ("uridine related compounds"). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods. In a preferred aspect the invention relates to a method of treatment of one or more side effects of statin therapy comprising administering to a subject in need of such treatment an effective amount of uridine, one of its biological precursors or a salt, ester, tautomer or analogue thereof either simultaneously, sequentially or separately to administration of an effective amount of at least one compound of Formula (I).

[sylviak]

Prof. Linnane is the director of the Center for Molecular Biology and Medicine.
(*http://www.cmbm.com.au/)
His bio reads:
"Professor Linnane has been involved with contemporary biochemical and molecular biological studies for over 40 years. These included membrane biochemistry, enzymology, gene structure and gene expression, formal and molecular genetics, monoclonal antibodies, peptide synthesis, oligonucleotide synthesis, lipid biochemistry and bioenergetics.

Current major interests: – Gastro intestinal cancers, diagnostics and therapeutics. The study of the molecular biology and medicine of the ageing process, particularly human skeleto-muscular changes, and associated diseases, and most recently the statin effects on muscle.

Prof. Linnane has 290 papers published in learned journals, numerous meeting abstracts, coeditor of two books, holder of several international patents.

He is a long-term association with the International Union of Biochemistry (a 54 nation organisation) beginning in 1977. These activities have included being the organiser of numerous international symposia, Founder of the Journal "Biochemistry and Molecular Biology International", Congress President of 12th International Congress.

(*http://ichal05.longevity-international.com/cms/details.asp?NewsID=133)

[cjbrooksjc]

GREAT FIND! This gentleman seems to be right on track with the 'premature aging' side effect of statin drugs as earlier reported by Dr. Graveline. Let's hope he has found something substantive. Recent reports of the involvement of the atrogin-1 gene in the muscle wasting side effect of statins may also be a part of this investigation; we'll soon see.

Many thanks, Sylvia.

Brooks

[sylviak]

The University of Freiburg's Ulrich Walker thinks such a medicine may already be for sale in Europe, a dietary supplement called NucleomaxX with Mitocnol,23 at least if the drug toxicities are of the mitochondrial kind. Cell studies in his lab suggest that Mitocnol's essential ingredient, uridine, can correct mitochondrial miscues.

After exposing liver cells (HepG2 hepatocytes) to 177 nM of ddC, Walker recorded severe mtDNA depletion (to 8 percent of normal levels), a steep drop in cell proliferation (to 20 percent of normal), severe intracellular steatosis (fat buildup), and up to a 350 percent jump in lactates. Uridine restored mtDNA levels to about 65 percent of normal and thereby "fully normalized" cell proliferation and intracellular lactate and lipid levels. Uridine worked this magic even when Walker continued treating the cells with ddC. The best results came at the highest uridine dose, 200 µM. Similar experiments with d4T and AZT -- but not ddI -- had similar results. Walker also found that uridine does not alter the 50 percent or 90 percent inhibitory concentrations of current nucleosides.

Given at a dose of three sachets per day for four days, NucleomaxX with Mitocnol reversed cellular toxicities in a person taking d4T. Walker and his colleagues have taken up to twice the recommended dose of this supplement, and no side effects emerged in this preliminary test. (The recommended dose is three sachets daily for three days, then no treatment for the rest of the month.) He plans formal tests to see whether this agent can help people with suspected mitochondrial toxicities such as lipoatrophy and polyneuropathy.

*http://www.thebody.com/content/art12244.html

[cjbrooksjc]

Sylvia:

I am hopeful again that we have found a restorative agent. Any idea what type of Uridine was used. I can't find a reference in the paper , and there are so many formulations.

Thanks for doing the heavy work and pursuing this.

Kind regards,

Brooks

[sylviak]

A more recent finding

*http://www.aegis.com/conferences/hiv-glasgow/2008/1758-2652-11-S1-P148.pdf
Summary:
Peripheral neuropathy and CNS neurodegeneration may be a toxic effect of some antiretroviral nucleoside analogues on mitochondria. We investigated if this neuropathology may be antagonized by uridine supplementation in vivo.
Result
Zalcitabine and to a lower extent zidovudine induced a significant peripheral and cerebral neuropathy with disrupted mitochondrial architecture, depleted mitochondrial DNA (mtDNA), and reduced levels of cytochrome Coxidase activity (COX) and mtDNA-encoded cytochrome
C subunit I (COX I). Mitocnol had no side-effects but attenuated or fully normalized all pathology of the peripheral and central nervous system.

Comments on the experiments:"Uridine replacement may only be effective for lipoatrophy by abrogating an effect of ongoing nucleoside use and its mechanism of action is not expected to help nucleosides such as ddI."- *http://www.i-base.info/htb/v6/htb6-1/Potential.html

[sylviak]

Further Comments to consider:
*http://www.catie.ca/tu.nsf/df739470490ae50d8525717f0061769d/9aab2e2b2b2f5d88852570f500594287!OpenDocument